bile duct cancer (Cancer)
Information
- Disease name
- bile duct cancer
- Disease ID
- DOID:4606
- Description
- "A biliary tract cancer that is located_in the bile duct." [url:http\://www.cancer.gov/dictionary/?CdrID=527370]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04660929 | Active, not recruiting | Phase 1 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | February 2, 2021 | December 31, 2024 |
| NCT04763642 | Active, not recruiting | N/A | The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone | January 1, 2020 | January 1, 2025 |
| NCT04853017 | Active, not recruiting | Phase 1 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors | October 4, 2021 | March 2026 |
| NCT04383210 | Active, not recruiting | Phase 2 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | September 29, 2020 | March 2025 |
| NCT05662488 | Active, not recruiting | FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy | September 1, 2020 | August 30, 2023 | |
| NCT04298021 | Active, not recruiting | Phase 2 | DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer | June 25, 2020 | December 31, 2024 |
| NCT04164069 | Active, not recruiting | Phase 1 | Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab | September 2, 2020 | December 31, 2023 |
| NCT04152018 | Active, not recruiting | Phase 1 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | November 13, 2019 | August 30, 2024 |
| NCT03525067 | Completed | Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies | February 1, 2017 | April 2, 2018 | |
| NCT00628186 | Completed | N/A | Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy | April 2005 | February 2008 |
| NCT00639314 | Completed | N/A | Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy | October 2005 | March 2011 |
| NCT00779688 | Completed | A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers | November 2008 | October 2010 | |
| NCT01134276 | Completed | N/A | Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers | August 2010 | May 2013 |
| NCT01256034 | Completed | Phase 4 | Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy | May 2009 | March 2012 |
| NCT01256047 | Completed | Phase 4 | Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy | May 2009 | March 2014 |
| NCT04596865 | Completed | Recurrence After Whipple's (RAW) Study | October 12, 2020 | June 30, 2023 | |
| NCT03058289 | Completed | Phase 1/Phase 2 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | February 9, 2017 | February 22, 2023 |
| NCT04476082 | Completed | Nutrition in Gastrointestinal Tumors | June 25, 2020 | December 6, 2022 | |
| NCT03111732 | Completed | Phase 2 | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | June 14, 2017 | November 8, 2021 |
| NCT03602079 | Completed | Phase 1/Phase 2 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | July 16, 2018 | January 12, 2022 |
| NCT05266300 | Completed | Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. | September 1, 2020 | October 1, 2022 | |
| NCT04937322 | Completed | Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry. | January 25, 2016 | March 30, 2021 | |
| NCT01640522 | Completed | N/A | Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms | January 2008 | December 2014 |
| NCT00280709 | Completed | Phase 4 | Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction | January 2006 | August 2010 |
| NCT01954745 | Completed | Phase 2 | Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma | September 2013 | June 2016 |
| NCT00183846 | Completed | Phase 1 | Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers | December 2000 | July 2009 |
| NCT02028845 | Completed | N/A | Loop-tipped Guidewire in Selective Biliary Cannulation | January 2014 | December 2015 |
| NCT02375880 | Completed | Phase 1 | Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder | June 2015 | July 2018 |
| NCT02591030 | Completed | Phase 2/Phase 3 | Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours | December 15, 2015 | January 16, 2020 |
| NCT00579865 | Completed | Quality Of Life in Patients With Malignant Biliary Obstruction | May 2005 | January 2010 | |
| NCT02821754 | Completed | Phase 2 | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | July 5, 2016 | December 31, 2022 |
| NCT02841800 | Completed | N/A | Intra-luminal Radiofrequency Ablation for Inoperable Malignant Biliary Stenosis | June 2016 | May 10, 2019 |
| NCT02853474 | Completed | Phase 3 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy | October 2016 | December 2022 |
| NCT06076252 | Enrolling by invitation | N/A | Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma | July 1, 2023 | August 31, 2028 |
| NCT05706974 | Not yet recruiting | Looking At Bile Duct Cancer Patient Experience Patterns in Medical Trials | February 2024 | February 2026 | |
| NCT06274879 | Not yet recruiting | Phase 2 | Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer | May 1, 2024 | April 30, 2026 |
| NCT05911425 | Not yet recruiting | Phase 2 | Combined Treatment of Treated Bile Duct Cancer | July 1, 2023 | June 30, 2025 |
| NCT06175845 | Not yet recruiting | N/A | Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma | February 2024 | July 2026 |
| NCT06453590 | Recruiting | N/A | Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents | February 4, 2020 | January 15, 2026 |
| NCT01915225 | Recruiting | Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer | July 21, 2013 | ||
| NCT02012699 | Recruiting | Integrated Cancer Repository for Cancer Research | November 1, 2013 | December 2099 | |
| NCT02628067 | Recruiting | Phase 2 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | December 18, 2015 | May 4, 2027 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04104230 | Recruiting | Quebec Pancreas Cancer Study | March 12, 2012 | January 2025 | |
| NCT04298008 | Recruiting | Phase 2 | AZD6738 Plus Durvalumab in Biliary Tract Cancer | June 25, 2020 | December 31, 2025 |
| NCT04907643 | Recruiting | N/A | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | October 5, 2021 | March 2026 |
| NCT04993131 | Recruiting | N/A | Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma | September 1, 2021 | May 31, 2045 |
| NCT05000294 | Recruiting | Phase 1/Phase 2 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | December 7, 2021 | December 2025 |
| NCT05155878 | Recruiting | Prognostic Factors in Periampullary Tumors and Cysts | September 1, 2021 | January 1, 2040 | |
| NCT05277766 | Recruiting | Phase 1 | Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer | November 21, 2022 | January 1, 2027 |
| NCT05286814 | Recruiting | Phase 2 | M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | October 24, 2022 | December 31, 2028 |
| NCT05346484 | Recruiting | Phase 1 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | May 17, 2022 | January 2025 |
| NCT05519319 | Recruiting | N/A | Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma | January 1, 2023 | June 1, 2026 |
| NCT05655949 | Recruiting | Phase 2 | Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio | February 13, 2024 | December 1, 2027 |
| NCT05712356 | Recruiting | Phase 2 | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | August 24, 2023 | December 2025 |
| NCT05849480 | Recruiting | Phase 1/Phase 2 | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | May 8, 2024 | June 1, 2042 |
| NCT05858736 | Recruiting | Phase 1 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors | July 11, 2023 | June 15, 2025 |
| NCT06028724 | Recruiting | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) | May 26, 2023 | May 31, 2030 | |
| NCT06043466 | Recruiting | Phase 1 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | August 11, 2023 | December 31, 2027 |
| NCT06048133 | Recruiting | Phase 2 | Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | March 8, 2024 | July 2025 |
| NCT06256055 | Recruiting | Phase 1 | Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors | March 5, 2024 | April 2025 |
| NCT06277531 | Recruiting | Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE) | March 1, 2024 | March 1, 2027 | |
| NCT06340620 | Recruiting | N/A | EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope | March 25, 2024 | December 2027 |
| NCT00624182 | Suspended | Phase 1 | Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer | February 2008 | December 2016 |
| NCT04076761 | Terminated | Phase 2 | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma | December 11, 2019 | September 30, 2022 |
| NCT01151761 | Terminated | Phase 2 | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation | January 2011 | July 2012 |
| NCT00832637 | Terminated | Phase 2 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers | August 2007 | March 15, 2017 |
| NCT04566133 | Terminated | Phase 2 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | February 15, 2022 | December 31, 2022 |
| NCT05418543 | Unknown status | N/A | CH-EUS in Diagnosis of Inoperable Bile Duct Tumors | January 1, 2022 | December 30, 2022 |
| NCT03763214 | Unknown status | N/A | PTFE Stents for Treatment of Malignant Biliary Strictures | March 1, 2018 | September 2020 |
| NCT03475966 | Unknown status | N/A | Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program | February 22, 2017 | June 30, 2022 |
| NCT03086993 | Unknown status | Phase 2/Phase 3 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | April 10, 2018 | May 2023 |
| NCT02954302 | Unknown status | N/A | Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy | September 2016 | December 2018 |
| NCT01438385 | Unknown status | Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders | July 2011 | December 30, 2017 | |
| NCT00356161 | Unknown status | Phase 2 | HAI Via Interventionally Implanted Port Catheter Systems | April 2002 | April 2008 |
| NCT04014478 | Unknown status | N/A | A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain | July 15, 2019 | July 15, 2021 |
| NCT03951324 | Unknown status | Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study | May 10, 2019 | December 31, 2019 | |
| NCT03788655 | Unknown status | Metal Stents (Moving Cell Stent) for Inoperable Tumors of the Bile Duct Tract | December 31, 2018 | June 2021 | |
| NCT00809081 | Unknown status | Phase 3 | Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy | July 2007 | January 2010 |
| NCT01317069 | Unknown status | Phase 2 | A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer | June 2010 | April 2013 |
| NCT01755013 | Unknown status | Phase 2/Phase 3 | Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma | February 2012 | March 22, 2018 |
| NCT01522573 | Unknown status | T-EUS for Gastrointestinal Disorders: A Multicenter Registry | November 2011 | December 30, 2018 | |
| NCT01111591 | Unknown status | Phase 4 | Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer | November 2008 | June 2017 |
| NCT01439698 | Unknown status | Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry | September 2011 | December 30, 2018 | |
| NCT02446379 | Withdrawn | Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery | |||
| NCT04404647 | Withdrawn | N/A | Irreversible Electroporation of Unresectable Liver Tumors | June 1, 2020 | March 30, 2025 |
- Disase is a (Disease Ontology)
- DOID:4607
- Cross Reference ID (Disease Ontology)
- ICD10CM:C24.0
- Cross Reference ID (Disease Ontology)
- ICD9CM:156.1
- Cross Reference ID (Disease Ontology)
- MESH:D001650
- Cross Reference ID (Disease Ontology)
- NCI:C2898
- Cross Reference ID (Disease Ontology)
- NCI:C7483
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:93790004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0005396
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0153453
- Exact Synonym (Disease Ontology)
- bile duct tumor
- Exact Synonym (Disease Ontology)
- Ca extrahepatic bile ducts
- Exact Synonym (Disease Ontology)
- malignant neoplasm of the extrahepatic bile duct